Clinical trials: Cancer, Ovarian
Breast Neoplasm, Pancreatic Neoplasm
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.
- Conditions
- Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm
- Trial name
- NCT00034281
- Testing
- TAK-165
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Takeda
Ovarian Cancer
Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003733
- Testing
- carboplatin, paclitaxel, topotecan hydrochloride
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- SmithKline Beecham
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma
- Trial name
- NCT06799065
- Testing
- ATX-295, ATX-295 and bevacizumab (or biosimilar)
- Where
- 11 sites in United States
- Volunteers
- 218 people
- Sponsor
- Accent Therapeutics
Ovarian Cancer, Cervical Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
This is an open phase I/Ib clinical study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and initial efficacy of RP903 in patients with advanced malignancies who have failed standard treatment or have no…
- Conditions
- Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Breast Cancer
- Trial name
- NCT06846099
- Testing
- RP903
- Where
- 23 sites in China
- Volunteers
- 69 people
- Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.
Carcinoma, Fallopian Tube Cancer
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
To evaluate whether AMG 386 in combination with paclitaxel and carboplatin is safe and well tolerated in the first-line treatment of high-risk stage I and stages II-IV epithelial ovarian, primary peritoneal and fallopian tube…
- Conditions
- Carcinoma, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01253681
- Testing
- AMG 386, paclitaxel and carboplatin
- Where
- 8 sites in Australia, Belgium and 1 more
- Volunteers
- 27 people
- Sponsor
- Amgen
Advanced Solid Tumor, Breast Cancer
A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.
- Conditions
- Advanced Solid Tumor, Breast Cancer, Non Small Cell Lung Cancer, Ovary Cancer
- Trial name
- NCT05465590
- Testing
- MB1707
- Sponsor
- Mainline Biosciences, Inc.
Epithelial Ovarian Cancer, Peritoneal Cancer
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02915523
- Testing
- entinostat, avelumab
- Where
- 12 sites in United States
- Volunteers
- 140 people
- Sponsor
- Syndax Pharmaceuticals
Ovarian, Breast
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response
- Conditions
- Ovarian, Breast, Prostate, Pancreatic
- Trial name
- NCT01078662
- Testing
- olaparib
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 298 people
- Sponsor
- AstraZeneca
Solid Tumor
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in…
- Trial name
- NCT04931823
- Testing
- CPO-100
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Epithelial Ovarian Cancer
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
The purpose of this study is to evaluate whether combination therapy with farletuzumab (MORAb-003), carboplatin, and pegylated liposomal doxorubicin (PLD) is safe.
- Trial name
- NCT01004380
- Testing
- Farletuzumab, Carboplatin, and PLD
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Morphotek
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Breast Cancer, Ovarian Cancer
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
This Pilot Study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- NCT05223218
- Testing
- Schirmer strip, a Class I Medical Device typically used to test for dry eye.
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Namida Lab
Platinum-resistant Ovarian Cancer, Refractory Ovarian Carcinoma
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
- Trial name
- NCT06315491
- Testing
- CBX-12
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cybrexa Therapeutics
Gynecologic Disease, Gynecologic Cancer
Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology
GynRAN is an international, multicentre, transversal, diagnostic and non-interventional study carried out in gynecology-obstetrics/gynecological oncology departments that aims to identify a diagnostic signature for gynecological…
- Conditions
- Gynecologic Disease, Gynecologic Cancer, Endometriosis, Ovarian Cancer
- Trial name
- GynRNA (NCT06392997)
- Testing
- Saliva sample
- Where
- 13 sites in France
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- ZIWIG
Epithelial Ovarian Cancer
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer
This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with…
- Trial name
- TREVI-OC-02 (NCT07851025)
- Testing
- Torvutatug samrotecan, Bevacizumab
- Where
- 186 sites in United States, Argentina and 22 more
- Volunteers
- 950 people
- Sponsor
- AstraZeneca
Recurrent Platinum Resistant Ovarian Cancer
Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer
This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell…
- Trial name
- CONCERTO (NCT02889900)
- Testing
- cediranib and olaparib
- Where
- 25 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Ovarian Carcinoma, Fallopian Tube Cancer
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
This is an open-label, multicenter study with a nonrandomized Phase 1 portion and an open-label, randomized, Phase 2 portion evaluating MLN8237 in combination with weekly paclitaxel in adult female participants with advanced…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma
- Trial name
- NCT01091428
- Testing
- Alisertib, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 191 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Ovarian Cancer
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
This is a double blind, randomized, placebo-controlled, 2-arm, Phase 2 trial investigating the efficacy and safety of combination therapy of pimasertib plus SAR245409 and pimasertib placebo administered once per day compared to…
- Trial name
- NCT01936363
- Testing
- Pimasertib once daily, SAR245409, Pimasertib twice daily
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 65 people
- Sponsor
- EMD Serono
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
The purpose of this study is to evaluate the safety and efficacy of BG-C9074 with bevacizumab (Arm A) versus bevacizumab monotherapy (Arm B) in adults with epithelial ovarian, fallopian tube, or primary peritoneal cancers who…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07811271
- Testing
- BG-C9074, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- BeOne Medicines
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2.
- Conditions
- Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT04180371
- Testing
- BT5528, Nivolumab
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 288 people
- Sponsor
- BicycleTx Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.